Last reviewed · How we verify

NCT05191693

Long-term Outcomes of Endoscopic Papillary Balloon Dilation for 8-12mm Bile Duct Stones: a Prospective Study

Completed Last updated 13 January 2022
What this trial tests

trial testing ERCP in Endoscopic Papillary Balloon Dilation in 72 participants. Completed in 29 August 2020.

Timeline
30 September 2018
Primary endpoint
29 August 2020
29 August 2020

Quick facts

Lead sponsorVenizelio General Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment72
Start date30 September 2018
Primary completion29 August 2020
Estimated completion29 August 2020
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

Venizelio General Hospital

Who can join

Eligibility, any sex, with Endoscopic Papillary Balloon Dilation or Bile Duct Stones. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators prospectively evaluated long-term outcomes of ELBPD+EST for CBD stones up to 8-12mm. EPBD+EST in patients with CBD stones up to 8-12mm appears to be associated with a very low (\<3%) rate of long-term stone recurrence. The efficacy of EPBD for 8-12mm stones warrants further exploration in randomized trials.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Endoscopic papillary large-balloon dilation with sphincterotomy for difficult common bile duct stones ≤12 mm: a prospective study.
    Velegraki M, Arna D, Nikolaou P, Psistakis A, et al · · 2024 · cited 1× · PMID 38223243 · DOI 10.20524/aog.2023.0855

Verify or expand the search:

Other trials of ERCP

Trials testing the same drug.

Other Venizelio General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05191693.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing